Cymarine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Cymarine
• 英文别名: 5,14-dihydroxy-3-(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde
• 化学式: C₃₀H₄₄O₉
• mdl: MFCD03225450
• 分子量: 548.7
• InChiKey: XQCGNURMLWFQJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS
  申请人：YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

  公开号：US20180369264A1

  公开（公告）日：2018-12-27

  The present invention relates to pharmaceutical combinations for the treatment of cardiovascular diseases and disorders. More particularly, the invention relates to pharmaceutical combinations comprising a cardiac steroids CS and at least one PI3K/Akt/m TOR inhibitor. The compositions of the invention may particularly be used for reducing the CS dose administered to a subject suffering from a cardiovascular disease or disorders, thereby reducing the side effects associated with CS therapy. The invention further provides methods of treatment of such diseases and disorders using the pharmaceutical combinations.